Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTPStrong Commercial Execution Maximizing Value of Existing Portfolio:ENTYVIO® Pen Launched in U.S. for Ulcerative Colitis; U.S. FDA Approval Decision.